HUP0104688A3 - Compositions and methods for the prevention or treatment of cancer and bone loss associated with cancer - Google Patents

Compositions and methods for the prevention or treatment of cancer and bone loss associated with cancer

Info

Publication number
HUP0104688A3
HUP0104688A3 HU0104688A HUP0104688A HUP0104688A3 HU P0104688 A3 HUP0104688 A3 HU P0104688A3 HU 0104688 A HU0104688 A HU 0104688A HU P0104688 A HUP0104688 A HU P0104688A HU P0104688 A3 HUP0104688 A3 HU P0104688A3
Authority
HU
Hungary
Prior art keywords
cancer
prevention
compositions
treatment
methods
Prior art date
Application number
HU0104688A
Other languages
English (en)
Hungarian (hu)
Original Assignee
Amgen Inc Thousand Oaks
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc Thousand Oaks filed Critical Amgen Inc Thousand Oaks
Publication of HUP0104688A2 publication Critical patent/HUP0104688A2/hu
Publication of HUP0104688A3 publication Critical patent/HUP0104688A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HU0104688A 1999-09-03 2000-08-18 Compositions and methods for the prevention or treatment of cancer and bone loss associated with cancer HUP0104688A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38954599A 1999-09-03 1999-09-03
PCT/US2000/022806 WO2001017543A2 (en) 1999-09-03 2000-08-18 Compositions and methods for the prevention or treatment of cancer and bone loss associated with cancer

Publications (2)

Publication Number Publication Date
HUP0104688A2 HUP0104688A2 (hu) 2002-03-28
HUP0104688A3 true HUP0104688A3 (en) 2004-07-28

Family

ID=23538715

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0104688A HUP0104688A3 (en) 1999-09-03 2000-08-18 Compositions and methods for the prevention or treatment of cancer and bone loss associated with cancer

Country Status (14)

Country Link
US (1) US20060019887A1 (https=)
EP (2) EP1140136B1 (https=)
JP (2) JP2003508491A (https=)
KR (1) KR20010085996A (https=)
CN (1) CN1345246A (https=)
AT (1) ATE362374T1 (https=)
AU (1) AU6788900A (https=)
CA (1) CA2349406C (https=)
DE (1) DE60034871T2 (https=)
ES (1) ES2287028T3 (https=)
HU (1) HUP0104688A3 (https=)
IL (1) IL142900A0 (https=)
WO (1) WO2001017543A2 (https=)
ZA (1) ZA200103565B (https=)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL117175A (en) 1995-02-20 2005-11-20 Sankyo Co Osteoclastogenesis inhibitory factor protein
DE69740107D1 (de) 1996-12-23 2011-03-10 Immunex Corp Rezeptor aktivator von nf-kappa b, rezeptor is mitglied der tnf rezeptor superfamilie
ES2263204T5 (es) 1997-04-15 2013-10-14 Daiichi Sankyo Company, Limited Nueva proteína y proceso para producir la misma
ES2284203T5 (es) 1997-04-16 2016-03-11 Amgen Inc. Proteínas de unión a osteoprotegerina y sus receptores
US6316408B1 (en) 1997-04-16 2001-11-13 Amgen Inc. Methods of use for osetoprotegerin binding protein receptors
AU762574B2 (en) 1998-05-14 2003-06-26 Immunex Corporation Method of inhibiting osteoclast activity
HUP0104126A3 (en) * 1998-10-28 2004-07-28 Sankyo Company Ltd Chuo Ku Remedies for bone metabolic errors
US20020090646A1 (en) * 2000-05-03 2002-07-11 Amgen Inc. Calcitonin-related molecules
WO2002024896A2 (en) 2000-09-22 2002-03-28 Immunex Corporation Screening assays for agonists or antagonists of receptor activat or of nf-kb
MXPA03011270A (es) * 2001-06-06 2004-03-18 Immunex Corp Uso de antagonistas rank para tratar cancer.
EP1270015A3 (en) * 2001-06-29 2004-02-25 Sankyo Company Limited A complex comprising OCIF and Polysaccharide
US7718776B2 (en) 2002-04-05 2010-05-18 Amgen Inc. Human anti-OPGL neutralizing antibodies as selective OPGL pathway inhibitors
US7585840B2 (en) 2002-04-10 2009-09-08 Merck Serono S.A. Use of osteoprotegerin for the treatment and/or prevention of fibrotic disease
EP1515743A2 (en) 2002-04-10 2005-03-23 Applied Research Systems ARS Holding N.V. Use of osteoprotegerin for the prevention and/or treatment of fibrosis/sclerosis
CA2487428A1 (en) * 2002-06-07 2003-12-18 Trillium Therapeutics Inc. Cd200-receptor mediated modulation of bone development
BRPI0519008A2 (pt) * 2004-12-13 2008-12-23 Evogenix Ltd proteÍnas variantes de osteoprotegerina
TW200714289A (en) * 2005-02-28 2007-04-16 Genentech Inc Treatment of bone disorders
ES2699077T3 (es) * 2009-06-12 2019-02-07 Sunovion Pharmaceuticals Inc Apomorfina sublingual
CN102242209B (zh) * 2011-07-05 2013-12-11 北京大学人民医院 基于多个基因辅助诊断多发性骨髓瘤患者的定量检测试剂盒
AU2012375257B2 (en) * 2012-03-31 2019-09-12 R-Pharm International, Limited Liability Company Osteoprotegerin derived composition and use thereof
KR20160127824A (ko) * 2014-03-06 2016-11-04 알-팜 오버씨즈, 인코포레이티드 오스테오프로테게린 유래의 rankl 억제제
KR101576904B1 (ko) * 2014-07-31 2015-12-14 (주)케어젠 파골세포 분화 및 활성 억제능을 갖는 펩타이드 및 이의 용도
EP3535585A1 (en) * 2016-11-04 2019-09-11 Aarhus Universitet Identification and treatment of tumors characterized by an overexpression of the neonatal fc receptor
CN110483647B (zh) * 2019-08-19 2021-02-09 重庆大学附属肿瘤医院 一种抗肿瘤多肽及其应用
JP2023525960A (ja) * 2020-04-15 2023-06-20 セラダプティブ インク 骨に標的治療薬を送達するための組成物および方法
KR20230118573A (ko) * 2020-11-11 2023-08-11 에이치큐 한 액티빈/tgf-베타 및 rankl의 이작용성 길항제 및 이의 용도

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4710473A (en) * 1983-08-10 1987-12-01 Amgen, Inc. DNA plasmids
AU610083B2 (en) * 1986-08-18 1991-05-16 Clinical Technologies Associates, Inc. Delivery systems for pharmacological agents
FR2640537B1 (fr) * 1988-12-21 1992-02-21 Levy Guy Installation et procede utilisant l'effet laser, pour la coupe ou la vaporisation de materiaux et tissus divers
US5013556A (en) * 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
JP3507486B2 (ja) * 1991-03-15 2004-03-15 アムジエン・インコーポレーテツド 顆粒球コロニー刺激因子の肺内投与
US5447851B1 (en) * 1992-04-02 1999-07-06 Univ Texas System Board Of Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells
ATE311895T1 (de) * 1992-05-26 2005-12-15 Immunex Corp Neue zytokine die cd30 binden
US5457035A (en) * 1993-07-23 1995-10-10 Immunex Corporation Cytokine which is a ligand for OX40
US5843901A (en) * 1995-06-07 1998-12-01 Advanced Research & Technology Institute LHRH antagonist peptides
US20050147611A1 (en) * 1995-12-22 2005-07-07 Amgen Inc. Combination therapy for conditions leading to bone loss
US20030207827A1 (en) * 1995-12-22 2003-11-06 William J. Boyle Osteoprotegerin
US6369027B1 (en) * 1995-12-22 2002-04-09 Amgen Inc. Osteoprotegerin
US6613544B1 (en) * 1995-12-22 2003-09-02 Amgen Inc. Osteoprotegerin
US7005413B1 (en) * 1995-12-22 2006-02-28 Amgen Inc. Combination therapy for conditions leading to bone loss

Also Published As

Publication number Publication date
IL142900A0 (en) 2002-04-21
ZA200103565B (en) 2002-05-03
ATE362374T1 (de) 2007-06-15
EP1140136A2 (en) 2001-10-10
CA2349406A1 (en) 2001-03-15
HUP0104688A2 (hu) 2002-03-28
DE60034871D1 (de) 2007-06-28
AU6788900A (en) 2001-04-10
KR20010085996A (ko) 2001-09-07
CA2349406C (en) 2011-01-11
DE60034871T2 (de) 2008-01-17
ES2287028T3 (es) 2007-12-16
WO2001017543A3 (en) 2001-07-26
WO2001017543A2 (en) 2001-03-15
JP2011225581A (ja) 2011-11-10
EP1140136B1 (en) 2007-05-16
US20060019887A1 (en) 2006-01-26
EP1800691A3 (en) 2007-10-31
EP1800691A2 (en) 2007-06-27
CN1345246A (zh) 2002-04-17
JP2003508491A (ja) 2003-03-04

Similar Documents

Publication Publication Date Title
HUP0104688A3 (en) Compositions and methods for the prevention or treatment of cancer and bone loss associated with cancer
AU6147401A (en) Compositions and methods for the treatment of cancer
AU2495200A (en) Compositions and methods for the treatment of tumor
AU2003200731A1 (en) Compositions and methods for the treatment of tumor
AU2003200722A1 (en) Compositions and methods for the treatment of tumor
AU2003200740A1 (en) Compositions and methods for the treatment of tumor
AU2212299A (en) Compositions and methods for the treatment of tumor
PT1231887E (pt) Método e composição para o tratamento de cicatrizes
KR100510795B1 (en) Compositions and Methods for the Treatment of Tumor
AU4205100A (en) Methods and compositions for the treatment of pancreatitis
HUP0103920A3 (en) Methods and compositions for the prevention and treatment of anemia
IL142906A0 (en) Methods and compositions for treating or preventing peripheral neuropathies
PL352931A1 (en) Compositions and uses of et743 for treating cancer
ZA200301204B (en) Compositions and methods for the diagnosis and treatment of tumor
AU8678501A (en) Compositions and methods for the diagnosis and treatment of tumor
ZA200003768B (en) Methods and compositions for treating diseases and conditions of the eye.
IL158206A0 (en) Compositions and methods for the prevention and treatment of human prostate cancer
IL143212A0 (en) Compositions and methods for the treatment of tumor
IL141426A0 (en) Compositions and methods for the treatment of tumor
PL368035A1 (en) Compositions and methods for the treatment of cancer
ZA200108256B (en) Compositions and methods for the treatment and diagnosis of breast cancer.
AU4228000A (en) Methods and compositions for the treatment and prevention of lung disease
HUP0200825A2 (en) Compositions and methods for the treatment and diagnosis of breast cancer
IL147410A0 (en) L-acetylcarnitine and l-propionylcarnitine containing composition for the prevention and treatment of kidney dysfunctions and diseases
IL141551A0 (en) Compositions and methods for the treatment of immune related diseases

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees